Form 4: Skye Bioscience Director Acquires 70,000 Stock Options
SEC Filing
Paul A. Grayson, a director of Skye Bioscience, Inc., acquired 70,000 stock options on October 28, 2024, according to a recent SEC filing.
Summary
- Paul A. Grayson, a director of Skye Bioscience, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on October 28, 2024, where Grayson acquired 70,000 stock options.
- The exercise price of the stock options is $5.15.
- The options vest in equal monthly installments over one year, starting October 28, 2024.
- The options expire on October 27, 2034.
- Following the transaction, Grayson directly owns 70,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 10/28/2024 | Date of the transaction where stock options were acquired and the vesting start date. |
| 10/27/2034 | Expiration date of the stock options. |
| 10/30/2024 | Date of the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.